Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2022-02-17 Earnings Release
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Full Year Trading Update
Earnings Release Classification · 98% confidence The document is a press release dated February 17, 2022, issued via RNS (London Stock Exchange's news service). It provides an update on trading for the year ended December 31, 2021, including unaudited revenue and cash figures, alongside operational updates on product commercialization (Accrufer®/Feraccru®). This structure—providing key financial highlights for a period (Full Year) and operational commentary—is characteristic of an Earnings Release (ER). It is not the full, audited Annual Report (10-K), nor is it a transcript (CT) or a formal presentation (IP). Since it contains specific financial results and trading updates, ER is the most appropriate classification over the general regulatory filing category (RNS). FY 2021
2022-02-17 English
KOL Investor Event on Iron Deficiency
Regulatory Filings Classification · 99% confidence The document is an announcement from Shield Therapeutics plc, dated February 4, 2022, regarding an upcoming Key Opinion Leader (KOL) Investor Event/Webinar scheduled for February 10, 2022, focusing on their product Accrufer®/Feraccru®. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing detailing financial results (ER or MDA). It is an announcement about an investor-facing event designed to present information to investors and analysts. This aligns best with an Investor Presentation (IP) or a general announcement. Since it is specifically announcing a presentation/webinar for investors featuring KOLs and management, 'Investor Presentation' (IP) is the most specific fit, although it could also be considered a general regulatory announcement (RNS) if the event itself wasn't the primary focus. Given the detailed nature of the event announcement, IP is preferred over the general RNS fallback. The document is short and serves to inform about an upcoming event, not to deliver the core content of a major report.
2022-02-04 English
Investor Presentation
Regulatory Filings Classification · 99% confidence The document is an announcement filed under RNS Number 7082X, dated January 7, 2022. The title explicitly states 'Investor Presentation' and details that the CEO is scheduled to present at the 'H.C. Wainwright BIOCONNECT Virtual Conference' on January 10, 2022. This content directly matches the definition of an Investor Presentation (IP). Although it is distributed via RNS, the primary subject matter is the presentation itself, not a general regulatory update or the announcement of a formal financial report.
2022-01-07 English
Licence Agreement in Canada for Accrufer®
M&A Activity Classification · 99% confidence The document begins with 'RNS Number : 4347X' and concludes with information about RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content announces a significant corporate event: an exclusive licence agreement for a drug (Accrufer®) in Canada, detailing financial terms (upfront payment, milestones, royalties). This type of announcement, which is a material corporate update distributed via the official regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (10-K, IR, ER) or a specific corporate action like a dividend (DIV) or share transaction (POS). While it is a significant announcement, RNS is the designated category for general regulatory announcements that don't fit elsewhere, and the structure strongly suggests an RNS release.
2022-01-05 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1941 characters) and contains the header 'RNS Number : 0500X'. It announces a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates that the document is a general regulatory announcement distributed via the RNS system, rather than a specific financial report like an ER, 10-K, or IR. Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory fallback category.
2021-12-30 English
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1924 characters) and contains the header 'RNS Number : 0494X'. It announces a 'Price Monitoring Extension' for a security, which is a specific, short-form operational announcement related to trading on the London Stock Exchange. It explicitly states that the information is provided by RNS, the news service of the London Stock Exchange, and is approved by the Financial Conduct Authority (FCA). This type of brief, operational regulatory update that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified as a general Regulatory Filing, which corresponds to the RNS code.
2021-12-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.